Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Management of epilepsy and pregnancy

Steven C Schachter, MD
Section Editors
Charles J Lockwood, MD, MHCM
Paul Garcia, MD
Deputy Editor
Janet L Wilterdink, MD


Over 90 percent of women with epilepsy have a normal pregnancy. This point should be emphasized to the patient who is likely to have many fears and anxieties regarding the risks. Nonetheless, women with epilepsy are at increased risk for a range of perinatal complications compared with the general population, including preeclampsia, preterm labor, and fetal and maternal mortality [1]. It is important for physicians and women with epilepsy to be aware of these as careful planning and management of pregnancy can increase the odds of a favorable outcome.

There are a number of important issues to be addressed by the physician when a woman with epilepsy becomes pregnant; these include:

Are antiseizure drugs necessary?

What effect do antiseizure drugs have on the fetus?

What effect does maternal epilepsy have on the fetus?

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 06, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. MacDonald SC, Bateman BT, McElrath TF, Hernández-Díaz S. Mortality and Morbidity During Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA Neurol 2015; 72:981.
  2. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998; 51:944.
  3. Sabers A. Influences on seizure activity in pregnant women with epilepsy. Epilepsy Behav 2009; 15:230.
  4. McGrath A, Sharpe L, Lah S, Parratt K. Pregnancy-related knowledge and information needs of women with epilepsy: a systematic review. Epilepsy Behav 2014; 31:246.
  5. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60:575.
  6. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992; 42:17.
  7. Billings RE. Decreased hepatic 5, 10-methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment. Mol Pharmacol 1984; 25:459.
  8. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009; 80:506.
  9. Ban L, Fleming KM, Doyle P, et al. Congenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort Study. PLoS One 2015; 10:e0131130.
  10. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:142.
  11. http://guideline.gov/summary/summary.aspx?doc_id=3994&nbr=3131. (Accessed on September 24, 2009).
  12. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338:131.
  13. American College of Obstetricians and Gynecologists. Seizure disorders in pregnancy. ACOG educational bulletin 231. Washington, DC, 1996.
  14. AAN guideline summary for clinicians. Management issues for women with epilepsy. www.aan.com/professionals/practice/pdfs/women_epilepsy.pdf (Accessed on March 7, 2005).
  15. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.
  16. Chadwick, D. The discontinuation of AED therapy. In: Recent Advances in Epilepsy, Pedley, TA, Meldrum, BS (Eds), 1985; 2:111.
  17. Vajda FJ, O'Brien T, Lander C, et al. The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. Epilepsia 2014; 55:1229.
  18. Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013; 54:1621.
  19. Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015; 56:1006.
  20. Nau, H, Schmidt-Gollwitzer, M, Kuhnz, W, et al. Antiepileptic drug disposition, protein binding and estradiol/progesterone serum concentration ratios during pregnancy. In: Advances in epileptology: XVth International Symposium. Porter, R, Mattson, R, Ward, AA Jr, et al (Eds), Raven, New York, 1984. p.239.
  21. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38:981.
  22. Lindhout D, Höppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984; 25:77.
  23. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.
  24. Reisinger TL, Newman M, Loring DW, et al. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav 2013; 29:13.
  25. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8:75.
  26. Lindhout D, Meinardi H, Meijer JW, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42:94.
  27. Hobbins JC. Diagnosis and management of neural-tube defects today. N Engl J Med 1991; 324:690.
  28. Nadel AS, Green JK, Holmes LB, et al. Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations. N Engl J Med 1990; 323:557.
  29. Chen SS, Perucca E, Lee JN, Richens A. Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. Br J Clin Pharmacol 1982; 13:547.
  30. Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990; 5:223.
  31. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013; 54:405.
  32. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005; 65:185.
  33. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251.
  34. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63:571.
  35. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70:2130.
  36. Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008; 49:1075.
  37. Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67:1297.
  38. Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009; 50:2163.
  39. Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48:1111.
  40. López-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav 2009; 15:372.
  41. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66:354.
  42. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47:504.
  43. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67:1497.
  44. Wegner I, Edelbroek P, de Haan GJ, et al. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia 2010; 51:2500.
  45. Westin AA, Nakken KO, Johannessen SI, et al. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009; 50:480.
  46. Holmes LB, Harvey EA, Brown KS, et al. Anticonvulsant teratogenesis: I. A study design for newborn infants. Teratology 1994; 49:202.
  47. Yerby MS. Problems and management of the pregnant woman with epilepsy. Epilepsia 1987; 28 Suppl 3:S29.
  48. Bleyer, WA, Skinner, AL. Fatal neonatal hemorrhage after maternal anticonvulsant therapy. JAMA 1976; 235:626.
  49. Mountain KR, Hirsh J, Gallus AS. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1970; 1:265.
  50. Cornelissen M, Steegers-Theunissen R, Kollée L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993; 168:884.
  51. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58:549.
  52. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology 1992; 42:8.
  53. Källén B. A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol Scand 1986; 73:253.
  54. Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 1975; 16:99.
  55. Hiilesmaa VK, Bardy A, Teramo K. Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985; 152:499.
  56. Kuhnz W, Koch S, Helge H, Nau H. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988; 11:147.
  57. Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009; 116:758.
  58. Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol 1979; 7:624.
  59. Pennell PB, Gidal BE, Sabers A, et al. Pharmacology of antiepileptic drugs during pregnancy and lactation. Epilepsy Behav 2007; 11:263.
  60. Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985; 72:460.
  61. Koup JR, Rose JQ, Cohen ME. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. Epilepsia 1978; 19:535.
  62. Meador KJ, Baker GA, Browning N, et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology 2010; 75:1954.
  63. Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 2014; 168:729.
  64. Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol 2013; 70:1367.
  65. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41:709.
  66. Uguz F, Sharma V. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Bipolar Disord 2016; 18:325.
  67. Newport DJ, Pennell PB, Calamaras MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics 2008; 122:e223.
  68. Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005; 46:775.
  69. Ohman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002; 43:1157.
  70. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005; 46:1621.